Subclassification of newly diagnosed glioblastomas through an immunohistochemical approach

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Conroy, Siobhan ^a   Kruyt, Frank A E ^a   Joseph, Justin V ^a   Balasubramaniyan, Veerakumar ^a   Bhat, Krishna P ^b   Wagemakers, Michiel ^a   Enting, Roelien H ^a   Walenkamp, Annemiek M E ^a   Den Dunnen, Wilfred F A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHITINASE; CHITINASE 3 LIKE 1 PROTEIN; CHROMOGRANIN A; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; GLIAL FIBRILLARY ACIDIC PROTEIN; HERMES ANTIGEN; ISOCITRATE DEHYDROGENASE 1; KI 67 ANTIGEN; NESTIN; NEUROFIBROMIN; NEUROFILAMENT PROTEIN; NEURON SPECIFIC NUCLEAR PROTEIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN P53; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; VIMENTIN; TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CLUSTER ANALYSIS; CYTOREDUCTIVE SURGERY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROSURGERY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; VERY ELDERLY; YOUNG ADULT; CLASSIFICATION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTOME;

EID: 84919933294     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115687     Document Type: Article

References (50)

1. Huse JT, Holland EC (2010) Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10: 319-331.
2. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, et al. (2011) Current concepts and management of glioblastoma. Ann Neurol 70: 9-21.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
5. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173.
6. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
7. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, et al. (2010) A multigene predictor of outcome in glioblastoma. Neuro Oncol 12: 49-57.
8. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, et al. (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64: 6503-6510.
9. Beier CP, Kumar P, Meyer K, Leukel P, Bruttel V, et al. (2012) The cancer stem cell subtype determines immune infiltration of glioblastoma. Stem Cells Dev 21: 2753-2761.
10. Ma X, Yoshimoto K, Guan Y, Hata N, Mizoguchi M, et al. (2012) Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. Neuro Oncol 14: 1153-1162.
11. Misra A, Pellarin M, Nigro J, Smirnov I, Moore D, et al. (2005) Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma. Clin Cancer Res 11: 2907-2918.
12. Wiltshire RN, Rasheed BK, Friedman HS, Friedman AH, Bigner SH (2000) Comparative genetic patterns of glioblastoma multiforme: Potential diagnostic tool for tumor classification. Neuro Oncol 2: 164-173.
13. Lee CH, Alpert BO, Sankaranarayanan P, Alter O (2012) GSVD comparison of patient-matched normal and tumor aCGH profiles reveals global copy-number alterations predicting glioblastoma multiforme survival. PLoS One 7: e30098.
14. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
15. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, et al. (2013) Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 24: 331-346.
16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
17. Federatie van Medisch Wetenschappelijke Verenigingen (2011) Verantwoord omgaan met lichaamsmateriaal ten behoeve van wetenschappelijk onderzoek: Gedragscode 2011. Federa, Rotterdam.
18. Horbinski C, Miller CR, Perry A (2011) Gone FISHing: Clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain Pathol 21: 57-73.
19. Sturn A, Quackenbush J, Trajanoski Z (2002) Genesis: Cluster analysis of microarray data. Bioinformatics 18: 207-208.
20. Specht K, Richter T, Muller U, Walch A, Werner M, et al. (2001) Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 158: 419-429.
21. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118: 599-601.
22. Capper D, Weissert S, Balss J, Habel A, Meyer J, et al. (2010) Characterization of R132H mutationspecific IDH1 antibody binding in brain tumors. Brain Pathol 20: 245-254.
23. von Deimling A, Korshunov A, Hartmann C (2011) The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21: 74-87.
24. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
25. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, et al. (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the european organization for research and treatment of cancer brain tumor group. Clin Cancer Res 16: 1597-1604.
26. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
27. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, et al. (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463: 318-325.
28. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, et al. (2002) Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21: 8404-8413.
29. Mendez MG, Kojima S, Goldman RD (2010) Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J 24: 1838-1851.
30. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, et al. (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4: e7752.
31. Tso CL, Freije WA, Day A, Chen Z, Merriman B, et al. (2006) Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 66: 159-167.
32. Varlet P, Soni D, Miquel C, Roux FX, Meder JF, et al. (2004) New variants of malignant glioneuronal tumors: A clinicopathological study of 40 cases. Neurosurgery 55: 1377-91: discussion 1391-2.
33. Donev K, Scheithauer BW, Rodriguez FJ, Jenkins S (2010) Expression of diagnostic neuronal markers and outcome in glioblastoma. Neuropathol Appl Neurobiol 36: 411-421.
34. Lee KH, Kang KJ, Moon KS, Jung TY, Jung S, et al. (2012) Prognostic significance of neuronal marker expression in glioblastomas. Childs Nerv Syst 28: 1879-1886.
35. De Bacco F, Casanova E, Medico E, Pellegatta S, Orzan F, et al. (2012) The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res 72: 4537-4550.
36. Pallud J, Dezamis E, Audureau E, Devaux B, Souillard-Scemama R, et al. (2012) Neuronal immunoexpression and a distinct subtype of adult primary supratentorial glioblastoma with a better prognosis. J Neurosurg 117: 476-485.
37. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
38. Joseph JV, Conroy S, Tomar T, Eggens-Meijer E, Bhat K, et al. (2014) TGF-beta is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion. Cell Death Dis 5: e1443.
39. Le Mercier M, Hastir D, Moles Lopez X, De Neve N, Maris C, et al. (2012) A simplified approach for the molecular classification of glioblastomas. PLoS One 7: e45475.
40. Motomura K, Natsume A, Watanabe R, Ito I, Kato Y, et al. (2012) Immunohistochemical analysisbased proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci 103: 1871-1879.
41. Popova SN, Bergqvist M, Dimberg A, Edqvist PH, Ekman S, et al. (2014) Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology 64: 365-379.
42. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153.
43. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
44. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, et al. (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11: 341-347.
45. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, et al. (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602.
46. Sulman EP, Guerrero M, Aldape K (2009) Beyond grade: Molecular pathology of malignant gliomas. Semin Radiat Oncol 19: 142-149.
47. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, et al. (2004) Genetic pathways to glioblastoma: A population-based study. Cancer Res 64: 6892-6899.
48. Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19: 764-772.
49. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, et al. (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: 479-483.
50. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, et al. (2012) Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A 109: 3041-3046.